PureTech Health (PRTC): Nasdaq ADS delisting
This situation live
PRTC PureTech Health
29 Apr 2026 · Intention to delist announced · −12% since
we have announced our intention to voluntarily delist our American Depositary Shares from Nasdaq and concentrate our listing on the London Stock Exchange, where the substantial majority of trading vol
Nasdaq ADS delisting
Intention to delist announced
Every step · 1
- 29 Apr 2026 Intention to delist announced – we have announced our intention to voluntarily delist our American Depositary Shares from Nasdaq and concentrate our listing on the London Stock Exchange,... ↗
What is happening
PureTech Health: Nasdaq ADS delisting – Intention to delist announced. ['Intention to delist announced']
- In short
- PureTech has announced its intention to voluntarily delist its ADSs from Nasdaq and concentrate its listing on the LSE. This was restated in the 29 Apr 2026 results. The company says it simplifies the structure and reduces cost and administrative burden.
- Announced
- 29 Apr 2026 · Intention to delist announced
- Action
- Voluntary delisting of ADSs from Nasdaq; LSE listing retained
- Rationale
- Most trading volume and liquidity is in London; lower cost and administrative burden
- Timetable
- Not stated
From the company's own announcements. Not investment advice.
Briefing
PureTech Health in 4 minutes
PureTech Health is a London-listed biotech that invents drugs, then moves them into separately financed companies. Its model produced Cobenfy, a schizophrenia drug whose early backing of $18.5m returned about $1.1bn...
- Act 1Karuna's $14bn sale and cash for shareholders
- Act 2A good drug and a funding gap
- Act 32026: outside money arrives
Also at PureTech Health 3 open
Project milestonesLYT-200 AML development – Fast Track and Phase 2 design set; funding sought
Disposal of a part (break-up)Deupirfenidone IPF Phase 3 – Phase 3 dosing; Celea financed
Capital returnCapital returns to shareholders – Intent stated; no amount or timing
Insider conviction1 director buying – £176k in 1 buy · closed
Insider conviction1 director buying – £289k in 1 buy · closed
PureTech Health – company page →